IMVARIA is a health‑tech company pioneering AI‑driven digital biomarker solutions (Software as a Medical Device) that help clinicians make earlier, more accurate diagnoses and prognoses while reducing the need for invasive testing.

The company focuses initially on serious pulmonary diseases and builds centralized AI services that analyze clinical testing and imaging (eg. CT) to generate novel physiologic signatures used as diagnostic adjuncts.

IMVARIA operates a cloud‑based AI Lab that receives de‑identified cases, runs automated machine‑learning models, and returns clinical reports. Key products include Fibresolve (FDA authorized adjunctive tool for idiopathic pulmonary fibrosis), ScreenDx (FDA 510(k) cleared screening algorithm for interstitial lung disease), and investigational tools such as Bronchosolve for lung nodule assessment.

These solutions are delivered as centralized, low‑burden services that integrate into clinician workflows without complex on‑site software installs.

Founded in 2019 by physician‑engineers from Google and Stanford, IMVARIA is based in Berkeley, CA. The team combines clinical and engineering expertise and has published and presented peer‑reviewed work and conference abstracts demonstrating clinical validation and real‑world use.

IMVARIA collaborates with leading clinical and industry partners, has secured strategic investments to scale its platform, and has active research programs and grants (including NIH SBIR) to extend its AI diagnostics into oncology and other areas.

IMVARIA is remote‑first and hiring engineering and commercial roles; open positions are posted on Wellfound. The company is headquartered in Berkeley, CA and can be contacted via [email protected].